Patent number: 9422251
Abstract: A ligand, a pharmaceutically acceptable salt, tautomer, or ester thereof, may be represented as: In the formula, X is selected from the group consisting of —(CH2)n—, —(CH2)n—O—, —(CH2)n—N(Rg)—, —(CH2)n—N(Rg)—C(O)— and —O—; Rg is hydrogen or (C1-C6)alkyl; G is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; G? is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; Rh is —H, —OH, NRaRb, or —CO2H; Rm is —H, —COOH, or substituted or unsubstituted —COO(C1-C6)alkyl; Ra and Rb are each independently H, substituted or unsubstituted (C1-C8)alkyl, or substituted or unsubstituted carboxy(C1-C8)alkylene; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
August 23, 2016
Assignee:
Molecular Insight Pharmaceuticals, Inc.
Inventors:
John W. Babich, Craig Zimmerman, John L. Joyal, Genliang Lu, Shawn Hillier, Kevin P. Maresca, John Marquis
